| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by LCR.
Page 8: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 2101 | 0 | 1 | 1066 1992 LANCET 339(8800):1057-1057 HAWKINS DF THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 7 | 8 |
| 2102 | 0 | 0 | 1075 1992 TERATOLOGY 46(5):417-418 LENZ W A PERSONAL PERSPECTIVE ON THE THALIDOMIDE TRAGEDY | 2 | 5 |
| 2103 | 0 | 0 | 1078 1992 TROPICAL DOCTOR 22(3):139-139 AWOFESO N THALIDOMIDE PERIPHERAL NEUROPATHY | 1 | 4 |
| 2104 | 0 | 0 | 1079 1992 TROPICAL DOCTOR 22(3):139-140 WATERS MFR THALIDOMIDE PERIPHERAL NEUROPATHY - REPLY | 2 | 4 |
| 2105 | 0 | 0 | 1081 1993 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 206:216-MEDI HE WX; ENGSTROM L; WALKER S; VOGELSANG G; LEONG KW SYNTHESIS OF THALIDOMIDE ANALOGS AND THEIR BIOLOGICAL POTENTIAL FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
| 2106 | 0 | 1 | 1083 1993 AMERICAN SCIENTIST 81(5):425-426 HOFFMAN M A 2ND CHANCE FOR THALIDOMIDE | 0 | 0 |
| 2107 | 0 | 0 | 1088 1993 BLOOD 82(10):A421-A421 VOGELSANG GB; COLVIN OM; ALTOMONTE V; PIANTADOSI S; HESS AD; SANTOS GW EFFECT OF THALIDOMIDE DOSE AND PLASMA-LEVEL ON PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
| 2108 | 0 | 0 | 1091 1993 BRITISH MEDICAL JOURNAL 307(6901):404-404 JOHN D DOCTOR WHO FOUND THALIDOMIDE DANGERS IS STRUCK OFF | 0 | 0 |
| 2109 | 0 | 1 | 1093 1993 CHEMICAL & ENGINEERING NEWS 71(28):5-5 BAUM R THALIDOMIDE BLOCKS VIRUS THAT CAUSES AIDS | 0 | 0 |
| 2110 | 0 | 0 | 1096 1993 CLINICAL RESEARCH 41(2):A496-A496 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND DRUG METABOLIC POLYMORPHISM | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2111 | 0 | 1 | 1097 1993 GASTROENTEROLOGY 104(4):A683-A683 COHEN LB; PEAREN S; IAZZETTA J THALIDOMIDE FOR INFLAMMATORY BOWEL-DISEASE - A PRELIMINARY-REPORT | 0 | 0 |
| 2112 | 0 | 0 | 1099 1993 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 34(4):1479-1479 YAN GC; PITTET N; HERBORT CP THE EFFECT OF THALIDOMIDE ON ENDOTOXIN-INDUCED UVEITIS IN RATS | 0 | 0 |
| 2113 | 0 | 0 | 1102 1993 JOURNAL OF INVESTIGATIVE DERMATOLOGY 100(4):492-492 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND DRUG METABOLIC POLYMORPHISM | 0 | 0 |
| 2114 | 0 | 0 | 1107 1993 NEW SCIENTIST 137(1862):6-6 DAYTON L THALIDOMIDE HERO FOUND GUILTY OF SCIENTIFIC FRAUD | 0 | 0 |
| 2115 | 0 | 0 | 1108 1993 PEDIATRIC DERMATOLOGY 10(3):283-285 MENNI S; IMONDI D; BRANCALEONE W; CROCI S RECURRENT GIANT APHTHOUS ULCERS IN A CHILD - PROTRACTED TREATMENT WITH THALIDOMIDE | 5 | 10 |
| 2116 | 0 | 0 | 1122 1994 BLOOD 84(10):A335-A335 PARKER PM; NADEMANEE A; ODONNELL MR; SNYDER DS; STEIN A; SMITH E; MOLINA A; STEPAN DE; CHAO N; NILAND JC; BLUME KG; FORMAN SJ NEUTROPENIA IS A COMPLICATION OF THALIDOMIDE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
| 2117 | 0 | 0 | 1123 1994 BLOOD 84(10):A431-A431 SCHLEGEL PG; FERNANDEZ LP; BAKER J; CHEN Y; CHAO NJ THALIDOMIDE DOES NOT MODULATE THE IL-2 RESPONSE OF ACTIVATED JURKAT CELLS AS MEASURED BY BETA-GAL-ACTIVITY AND BY IL-2 PRODUCTION | 1 | 1 |
| 2118 | 0 | 0 | 1125 1994 BRITISH MEDICAL JOURNAL 308(6931):739-739 CHRISTIE B THALIDOMIDE VICTIMS WIN REVIEW OF COMPENSATION | 2 | 2 |
| 2119 | 0 | 0 | 1126 1994 BRITISH MEDICAL JOURNAL 308(6936):1061-1061 ROCHA J THALIDOMIDE GIVEN TO WOMEN IN BRAZIL | 3 | 4 |
| 2120 | 0 | 3 | 1129 1994 BRITISH MEDICAL JOURNAL 308(6944):1636-1636 READ AP THALIDOMIDE MAY BE A MUTAGEN - COMMENT | 11 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2121 | 0 | 0 | 1134 1994 CHEMISTRY IN BRITAIN 30(4):280-280 CAREY J THALIDOMIDE DEBATE - REPLY | 0 | 0 |
| 2122 | 0 | 0 | 1135 1994 CHEMISTRY IN BRITAIN 30(4):280-280 HUNT JR THALIDOMIDE DEBATE | 0 | 0 |
| 2123 | 0 | 12 | 1136 1994 CHIRALITY 6(4):221-224 KNOCHE B; BLASCHKE G STEREOSELECTIVITY OF THE IN-VITRO METABOLISM OF THALIDOMIDE | 15 | 19 |
| 2124 | 0 | 0 | 1137 1994 CLINICAL RESEARCH 42(2):A142-A142 RIFKIN IR; MCHUGH SM; BRADLEY JR; THIRU S; EWAN PW; LOCKWOOD CM INDUCTION OF TH2, AND INHIBITION OF TH1, LYMPHOCYTE-RESPONSES BY THALIDOMIDE | 0 | 0 |
| 2125 | 0 | 0 | 1143 1994 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 35(4):1996-1996 DAMATO RJ; LOUGHMAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 0 | 0 |
| 2126 | 0 | 1 | 1149 1994 LANCET 343(8900):795-796 CUTLER J THALIDOMIDE REVISITED | 4 | 5 |
| 2127 | 0 | 0 | 1156 1994 PANMINERVA MEDICA 36(1):1-4 VOSGERAU JCB AUTOIMMUNITY IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND THE USE OF THALIDOMIDE | 3 | 3 |
| 2128 | 0 | 0 | 1157 1994 PANMINERVA MEDICA 36(1):44-47 VOSGERAU JCB ATYPICAL HERPES SIMPLE - A SIGN OF TOXOPLASMOSIS ACTIVITY IN AIDS PATIENTS AND THE USE OF THALIDOMIDE | 0 | 1 |
| 2129 | 0 | 0 | 1161 1994 REVISTA BRASILEIRA DE GENETICA 17(4):449-464 SALDANHA PH THE THALIDOMIDE-TRAGEDY AND THE BIRTH OF EXPERIMENTAL TERATOLOGY | 0 | 0 |
| 2130 | 0 | 8 | 1167 1995 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 122(9):609-611 Safa G; Joly P; Boullie MC; Thomine E; Lauret P Treatment of 2 cases of Melkersson-Rosenthal syndrome with thalidomide | 3 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2131 | 0 | 0 | 1172 1995 ARTHRITIS AND RHEUMATISM 38(6):R10-R10 OLIVER SJ; CHENG TP; BANQUERIGO ML; BRAHN E THALIDOMIDE ANALOGS SUPPRESS RAT COLLAGEN ARTHRITIS | 1 | 2 |
| 2132 | 0 | 0 | 1173 1995 ARTHRITIS AND RHEUMATISM 38(9):769-769 SCOVILLE CD OPEN TRIAL OF THALIDOMIDE IN THE TREATMENT OF RHEUMATOID-ARTHRITIS | 0 | 0 |
| 2133 | 0 | 0 | 1176 1995 BLOOD 86(10):1577-1577 Browne PV; Wagner J; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Enright H Response to thalidomide therapy in patients with refractory chronic graft-versus-host disease. | 0 | 0 |
| 2134 | 0 | 0 | 1180 1995 CHEMISTRY IN BRITAIN 31(10):760-760 [Anon] THALIDOMIDE REVIVAL | 0 | 0 |
| 2135 | 0 | 0 | 1188 1995 DRUG SAFETY 12(6):364-369 SCHULER U; EHNINGER G THALIDOMIDE - RATIONALE FOR RENEWED USE IN IMMUNOLOGICAL DISORDERS | 25 | 36 |
| 2136 | 0 | 0 | 1189 1995 ENVIRONMENTAL HEALTH PERSPECTIVES 103(2):132-132 [Anon] RETHINKING THALIDOMIDE | 0 | 0 |
| 2137 | 0 | 0 | 1190 1995 EUROPEAN CHEMICAL NEWS 63(1667):8-8 [Anon] GUINNESS TOPS UP THALIDOMIDE FUND | 0 | 0 |
| 2138 | 0 | 0 | 1200 1995 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 36(4):S225-S225 DAMATO RJ; KENYON BM FURTHER-STUDIES EXAMINING THE EFFECTS OF THALIDOMIDE ON ANGIOGENESIS | 0 | 0 |
| 2139 | 0 | 0 | 1203 1995 JOURNAL OF INVESTIGATIVE DERMATOLOGY 105(3):479-479 CHARUE D; CHAUVIN E; DUGUET C; REVUZ J; BAGOT M THALIDOMIDE DECREASES THE PRODUCTION OF GM-CSF AND TNF-ALPHA IN MIXED EPIDERMAL-CELL LYMPHOCYTE-REACTION | 2 | 2 |
| 2140 | 0 | 0 | 1208 1995 KIDNEY INTERNATIONAL 47(2):672-672 RIFLKIN IR; MCHUGH SM; BRADLEY JR; THIRU S; EWAN PW; LOCKWOOD CM THALIDOMIDE AS TREATMENT FOR REFRACTORY SYSTEMIC VASCULITIS - POSSIBLE MECHANISM OF ACTION | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2141 | 0 | 0 | 1209 1995 LANCET 346(8985):1289-1289 THOMPSON C THALIDOMIDE EFFECTIVE FOR AIDS-RELATED ORAL ULCERS | 5 | 10 |
| 2142 | 0 | 0 | 1213 1995 MOLECULAR BIOLOGY OF THE CELL 6:1195-1195 DESESSO JM; HARRIS SB; SCIALLI AR; GOERINGER GC EARLY MICROSCOPIC OBSERVATIONS OF THALIDOMIDE-INDUCED LIMB DEFECTS IN NEW-ZEALAND WHITE-RABBITS | 0 | 0 |
| 2143 | 0 | 0 | 1217 1995 NATURE MEDICINE 1(12):1230-1230 GERSHON D FINDING NEW USES FOR THALIDOMIDE | 3 | 5 |
| 2144 | 0 | 0 | 1218 1995 NEUROLOGY 45(4):A168-A168 CLAVELOU P; COLAMARINO R; DINCAN M; DEFFOND D; TOURNILHAC M; SOUTEYRAND P THALIDOMIDE-RELATED NEUROPATHY - A PROSPECTIVE, CLINICAL, ELECTROMYOGRAPHIC TRIAL | 1 | 1 |
| 2145 | 0 | 0 | 1221 1995 SEARCH 26(10):290-290 WESTMORE A HEREDITY OF THALIDOMIDE DEFORMITY DISPUTED | 0 | 0 |
| 2146 | 0 | 0 | 1223 1996 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 212:140-MEDI Niwayama S; Turk B; Liu J Potent inhibition of tumor necrosis factor-alpha by tetrafluoro-thalidomide and tetrafluorophthalimides | 0 | 0 |
| 2147 | 0 | 0 | 1224 1996 AIDS 10:P60-P60 FeregrinoGoyos M; GomezCaro WH; AlvaradoDiez R; Yieyra MPM; TorrasGiner V Thalidomide and ketoprofen reduce the incidence of adverse events of interleukin 2 and enhance the antiviral activity of CD8 in HIV/AIDS patients. | 0 | 0 |
| 2148 | 0 | 0 | 1225 1996 AIDS 10:P102-P102 MacRedmond R; Keating S; Armstrong S; Ryan M; Mulcahy FM The use of oral thalidomide in the treatment of oesophageal ulceration in AIDS. | 0 | 0 |
| 2149 | 0 | 0 | 1227 1996 AIDS PATIENT CARE AND STDS 10(1):51-51 [Anon] Thalidomide effective in treating AIDS-related mouth ulcers | 0 | 0 |
| 2150 | 0 | 0 | 1228 1996 AIDS PATIENT CARE AND STDS 10(4):263-263 [Anon] Thalidomide trial for diarrhea | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2151 | 0 | 0 | 1229 1996 AMERICAN JOURNAL OF EPIDEMIOLOGY 143(11):6-6 Yang Q; Khoury MJ; James LM; Olney RS; Paulozzi LJ The return of thalidomide? Are birth defects surveillance systems ready? | 0 | 1 |
| 2152 | 0 | 0 | 1241 1996 ARTHRITIS AND RHEUMATISM 39(9):1352-1352 Stevens RJ; Andujar C; Edwards C; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus. | 0 | 1 |
| 2153 | 0 | 0 | 1242 1996 ARTHRITIS AND RHEUMATISM 39(9):1353-1353 Sato EI; Assis LSS; Furtado R Long-term thalidomide therapy for cutaneous lesions of systemic lupus erythematosus (SLE) | 0 | 0 |
| 2154 | 0 | 0 | 1243 1996 ARTHRITIS AND RHEUMATISM 39(9):1524-1524 Lee S; Klausner J; Oliver S; Kaplan G; McCullagh E Treatment of rheumatoid arthritis (RA) with thalidomide | 1 | 1 |
| 2155 | 0 | 0 | 1247 1996 BLOOD 88(10):2423-2423 Flowers MED; Tapscott SJ; Emerson J; Emerson MV; Reagan T; Taylor L; Ajer T; Siadak M; Sanders J; Zwingenberger K; Willsmann K; Appelbaum F; Sullivan KM Incidence of peripheral neuropathy (PN) prior to thalidomide treatment for chronic graft-versus-host disease (GVHD). | 0 | 0 |
| 2156 | 0 | 0 | 1248 1996 BLOOD 88(10):2424-2424 Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Middleton G; Eisen T; Singhal S Thalidomide for acute or chronic graft-versus-host disease. | 0 | 0 |
| 2157 | 0 | 0 | 1262 1996 FASEB JOURNAL 10(6):303-303 Shannon EJ; Sandoval F; Krahenbuhl J Hydrolysis of thalidomide abrogates its ability to enhance IL-2 or to suppress TNF-alpha. | 0 | 0 |
| 2158 | 0 | 0 | 1265 1996 IMMUNOLOGY 89:ORI27-ORI27 Marriott JB; Cookson S; Westby M; Guckian M; Dalgleish AG The effect of a thalidomide analogue on TNF-alpha/cytokine production in vitro | 0 | 0 |
| 2159 | 0 | 0 | 1266 1996 IMMUNOLOGY 89:E51-E51 Guckian M; Marriott JB; Cookson S; Westby M; Dalgleish G Thalidomide analog 3052 reduces NK activity and PHA-induced proliferation in vitro. | 0 | 0 |
| 2160 | 0 | 0 | 1272 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):546-546 Ozaki S; Yamana T; Kita M; Honda Y Effect of thalidomide on experimental choroidal neovascularization in pigmented rats | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2161 | 0 | 0 | 1273 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):572-572 Tsujikawa M; Saito Y; Tatebayashi M; Tano Y The inhibitory effect of thalidomide for experimental preretinal neovascularization by laser-induced venous occlusion in rats. | 0 | 0 |
| 2162 | 0 | 0 | 1274 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):3032-3032 Lansing MB; Dixit S; Glaser BM The effect of systemic thalidomide and amiloride on neovascularization in the rabbit corneal micropocket essay | 0 | 0 |
| 2163 | 0 | 0 | 1275 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):4015-4015 Zhang EP; Pleyer U; Hoffmann F; Hartmann C Effect of thalidomide on experimental keratoplasty | 0 | 0 |
| 2164 | 0 | 0 | 1278 1996 JOURNAL OF INVESTIGATIVE DERMATOLOGY 106(4):845-845 Smith C; Friednash M; Nguyen C; Knauf T; Walsh P Failure of thalidomide as an anti-angiogenesis factor in a murine melanoma model | 2 | 3 |
| 2165 | 0 | 0 | 1284 1996 LANCET 348(9038):1370-1370 Barnett AA FDA encourages firms to test thalidomide | 0 | 0 |
| 2166 | 0 | 0 | 1288 1996 NEUROLOGY 46(2):3015-3015 Openshaw H; Slatkin NE; Parker P Thalidomide neuropathy in bone marrow transplantation | 0 | 0 |
| 2167 | 0 | 0 | 1289 1996 NEUROLOGY 46(2):27003-27003 Chaudhry V; Cornblath D; Corse A; Freimer M; SimmonsOBrien E; Vogelsang G Thalidomide-induced neuropathy: Clinical and electrophysiological features | 0 | 0 |
| 2168 | 0 | 0 | 1290 1996 NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY 22(5):456-456 Chakrabarty A; Bridges LR Cerebral malformation in a patient with thalidomide related phocomelia | 0 | 0 |
| 2169 | 0 | 0 | 1294 1996 REPRODUCTIVE TOXICOLOGY 10(1):1-2 Robert E Thalidomide and isotretinoin - Why treat them differently? | 2 | 6 |
| 2170 | 0 | 6 | 1296 1996 SLEEP 19(2):116-116 Kanbayashi T; Nishino S; Tafti M; Hishikawa Y; Dement WC; Mignot E Thalidomide, immune modulation and narcolepsy | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2171 | 0 | 0 | 1299 1997 AIDS PATIENT CARE AND STDS 11(4):292-292 [Anon] Limited course of thalidomide effective in treating AIDS-related mouth ulcers | 0 | 0 |
| 2172 | 0 | 0 | 1300 1997 AIDS PATIENT CARE AND STDS 11(4):292-293 [Anon] Clinical sites initiated for thalidomide aphthous ulcer study | 0 | 0 |
| 2173 | 0 | 0 | 1301 1997 AIDS PATIENT CARE AND STDS 11(4):296-296 [Anon] Positive results reported for thalidomide in AIDS wasting | 0 | 0 |
| 2174 | 0 | 1 | 1307 1997 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 54(13):1485-1486 [Anon] Thalidomide heals HIV-related oral ulcers, but caution is required | 0 | 0 |
| 2175 | 0 | 0 | 1308 1997 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 54(20):2270-& Miller JL Thalidomide recommended for approval under tight restrictions | 2 | 2 |
| 2176 | 0 | 0 | 1311 1997 ANNALS OF INTERNAL MEDICINE 127(10):951-952 Vanchieri C Preparing for thalidomide's comeback | 1 | 1 |
| 2177 | 0 | 0 | 1313 1997 ARTHRITIS AND RHEUMATISM 40(9):210-210 Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Randomised and placebo controlled trial of two different doses of thalidomide in Behcet's syndrome | 0 | 0 |
| 2178 | 0 | 0 | 1315 1997 BLOOD 90(10):1673-1673 Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide is very effective for chronic GVHD but has no activity in acute GVHD. | 0 | 0 |
| 2179 | 0 | 0 | 1316 1997 BLOOD 90(10):4423-4423 Mehta P; Gian VG; Smith SP; Beltz SE; Wingard JR Thalidomide is not effective for acute graft-versus-host disease. | 0 | 0 |
| 2180 | 0 | 0 | 1320 1997 BRITISH MEDICAL JOURNAL 315(7110):699-699 Rutter T Thalidomide ban to be lifted in the US | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2181 | 0 | 0 | 1321 1997 CHEMISTRY & INDUSTRY (18):714-714 [Anon] Thalidomide for US | 0 | 0 |
| 2182 | 0 | 0 | 1330 1997 CLINICAL PHARMACOLOGY & THERAPEUTICS 61(2):PI44-PI44 OToole EA; Nasca MR; Palicharla P; West DP; Woodley DT Thalidomide increases keratinocyte proliferation and chemokine secretion in vitro | 0 | 0 |
| 2183 | 0 | 0 | 1331 1997 CLINICAL PHARMACOLOGY & THERAPEUTICS 61(2):PIV89-PIV89 Donahue SR; Collins JM; Flockhart DA; Abernethy DR; Trapnell CB Thalidomide pharmacokinetics do not change with chronic administration | 0 | 0 |
| 2184 | 0 | 0 | 1334 1997 DRUG NEWS & PERSPECTIVES 10(8):506-506 [Anon] Celgene's thalidomide approvable for ENL | 0 | 0 |
| 2185 | 0 | 0 | 1335 1997 EUROPEAN CHEMICAL NEWS 68(1780):51-51 [Anon] Celgene - FDA approves thalidomide's use against ENL | 0 | 0 |
| 2186 | 0 | 0 | 1337 1997 FORTUNE 136(6):36-& McLean B Thalidomide .2. | 0 | 0 |
| 2187 | 0 | 0 | 1346 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):1240-1240 Lesk MR; Ponomarenko S; Filion B; Burnier M Effect of oral thalidomide on prolongation of rabbit sclerostomy function. | 0 | 0 |
| 2188 | 0 | 2 | 1347 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):1680-1680 Joussen AM; Kruse FE; Becker M; Rohrschneider K; Volcker HE Thalidomide inhibits angiogenesis induced by vascular endothelial growth factor | 0 | 0 |
| 2189 | 0 | 0 | 1348 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):4467-4467 DAmato RJ; Verheul HMW; Panigrahy D; Yuan J Combination antiangiogenic therapy with thalidomide and nonsteroidal anti-inflammatory drugs (NSAIDs) | 0 | 0 |
| 2190 | 0 | 0 | 1349 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):5409-5409 Baatz H; Tonnessen B; Pleyer U; Hartmann C Thalidomide inhibits leukocyte-endothelium-interaction in endotoxin-induced uveitis | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2191 | 0 | 0 | 1350 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(5):379-379 Nightingale SL Workshop on thalidomide | 0 | 0 |
| 2192 | 0 | 0 | 1351 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(14):1135-1137 Marwick C Thalidomide back - Under strict control | 10 | 13 |
| 2193 | 0 | 0 | 1352 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):20-20 Welles L; Little R; Wyvill K; Pluda J; Figg W; Lietzau J; Merced T; Humphrey R; Yarchoan R Preliminary results of a phase II study of oral thalidomide in patients with HIV infection and Kaposi's sarcoma (KS) | 2 | 3 |
| 2194 | 0 | 0 | 1353 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):76-76 Bower M; Howard M; Gracie F; Phillips R; Fife K A phase II study of thalidomide for Kaposi's sarcoma: Activity and correlation with KSHV DNA load | 1 | 2 |
| 2195 | 0 | 0 | 1355 1997 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 99(1):679-679 James DE; Jaffarian A; Biggs DF The effects of thalidomide on TNF alpha production from guinea pig alveolar macrophages in vitro and on airways' hyperresponsiveness in vivo. | 0 | 0 |
| 2196 | 0 | 0 | 1358 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):179-179 Nasca MR; OToole EA; Palicharla P; West DP; Woodley DT Thalidomide increases both human keratinocyte proliferation and migration | 0 | 0 |
| 2197 | 0 | 0 | 1359 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):721-721 Hughes MH; Brander TR; Aronson IK; Eilers D; Fiedler BC Thalidomide therapy for discoid and systemic lupus erythematosus. | 0 | 0 |
| 2198 | 0 | 0 | 1360 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):797-797 Wong J; Brocato D; Kumar R The effect of thalidomide on murine hemangioendothelioma | 0 | 0 |
| 2199 | 0 | 10 | 1361 1997 JOURNAL OF PARENTERAL AND ENTERAL NUTRITION 21(4):233-234 Vromen A; Spira RM; Bercovier H; Berry E; Freund HR Pentoxifylline and thalidomide fail to reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat | 0 | 2 |
| 2200 | 0 | 0 | 1363 1997 JOURNAL OF THE NATIONAL CANCER INSTITUTE 89(20):1480-1481 Saphir A Jekyll and Hyde: A new license for thalidomide? | 5 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2201 | 0 | 0 | 1364 1997 JOURNAL OF WOMENS HEALTH 6(6):614-615 White K Thalidomide may be approved after decades-long US ban | 0 | 0 |
| 2202 | 0 | 0 | 1365 1997 LANCET 349(9045):111-111 Barnett AA Company applies to market thalidomide in USA | 0 | 0 |
| 2203 | 0 | 1 | 1366 1997 LANCET 350(9081):873-873 Ault A Thalidomide comes close to US approval | 1 | 1 |
| 2204 | 0 | 0 | 1374 1997 NATURE BIOTECHNOLOGY 15(11):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 1 |
| 2205 | 0 | 0 | 1375 1997 NATURE BIOTECHNOLOGY 15(12):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 0 |
| 2206 | 0 | 0 | 1376 1997 NATURE MEDICINE 3(1):8-8 Cimons M Thalidomide resurfaces for FDA consideration | 1 | 1 |
| 2207 | 0 | 0 | 1377 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 355(4):545-545 Stahl W; Nicolai S; Sies H Stimulation of gap junctional communication by thalidomide and thalidomide analogs in human skin fibroblasts | 0 | 0 |
| 2208 | 0 | 1 | 1382 1997 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1087-1087 Jacobson JM; Greenspan JS; Spritzler J Thalidomide for aphthous ulcers in HIV infection - Reply | 0 | 0 |
| 2209 | 0 | 2 | 1385 1997 SCIENTIST 11(3):1-& Brown KS New uses for thalidomide yielding valuable lessons | 1 | 4 |
| 2210 | 0 | 0 | 1387 1997 SEARCH 28(8):239-239 [Anon] Inheriting thalidomide deformities | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2211 | 0 | 0 | 1391 1998 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 216:U267-U267 Swartz GM; Shah JH; Fogler WE; Papathanassiu A; Madsen JW; Green SJ 2-methyl-2-phthalimidino-glutaric acid, a partially-reduced analog of thalidomide, is a potent inhibitor of B16 melanoma metastases. | 0 | 0 |
| 2212 | 0 | 0 | 1393 1998 AIDS PATIENT CARE AND STDS 12(3):231-231 [Anon] Thalidomide studied in asymptomatic patients | 0 | 0 |
| 2213 | 0 | 0 | 1395 1998 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 55(17):1746-+ Kepple SR Thalidomide approval brings tight restrictions on access | 1 | 1 |
| 2214 | 0 | 0 | 1401 1998 ARTHRITIS AND RHEUMATISM 41(9):S60-S60 Scoville CD Open trial using methotrexate and thalidomide in the treatment of rheumatoid arthritis. | 2 | 2 |
| 2215 | 0 | 0 | 1402 1998 ARTHRITIS AND RHEUMATISM 41(9):S98-S98 Oliver SJ; Freeman SL; Kaplan G Thalidomide and analog CC1089 in rat adjuvant arthritis. | 0 | 0 |
| 2216 | 0 | 0 | 1403 1998 ARTHRITIS AND RHEUMATISM 41(9):S108-S108 Ordi-Ros J; Cortes F; Martinez N; Montse M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease. | 0 | 0 |
| 2217 | 0 | 0 | 1405 1998 ASM NEWS 64(10):557-558 Fox JL Thalidomide approved for treating leprosy | 1 | 1 |
| 2218 | 0 | 0 | 1410 1998 BIOTECHNOLOGY LAW REPORT 17(3):361-362 [Anon] FDA grants orphan drug designation to thalidomide as treatment for primary brain cancers | 0 | 0 |
| 2219 | 0 | 0 | 1411 1998 BIOTECHNOLOGY LAW REPORT 17(5):596-597 [Anon] Notorious teratogen wins FDA approval for leprosy - Thalidomide will be most tightly regulated drug ever | 0 | 0 |
| 2220 | 0 | 0 | 1412 1998 BLOOD 92(10):235B-235B Costa PT; Leaf RMLV; Morais LO; Ribeiro RA Thalidomide (TLD) and pentoxifylline (PTX) prevent the development of chronic cardiomyopathy provoked by doxorubicin (DXR) in rats without inhibiting its antitumoral effect. | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2221 | 0 | 0 | 1413 1998 BLOOD 92(10):279B-279B Lim SH; Maclean R Thalidomide in IgA multiple myeloma. | 0 | 0 |
| 2222 | 0 | 0 | 1414 1998 BLOOD 92(10):318A-318A Singhal S; Mehta J; Eddlemon P; Gray P; Cromer J; Desikan R; Ayers D; Siegel D; Munshi N; Anaissie E; Kantarjian H; Zeldis J; Barlogie B Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). | 0 | 20 |
| 2223 | 0 | 0 | 1415 1998 BLOOD 92(10):344B-344B Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide in GVHD - S anti-GVHD effect separable from the antiangiogenesis? | 0 | 4 |
| 2224 | 0 | 0 | 1416 1998 BONE MARROW TRANSPLANTATION 21:S113-S113 Anagnostopoulos A; Fassas A; Giannaki E; Sakellari I; Tzarou V; Smias C; Lalayanni C; Papaioannou G; Gakos E Treatment of resistant chronic GVHD with thalidomide. | 0 | 0 |
| 2225 | 0 | 0 | 1423 1998 CHEMISTRY & INDUSTRY (15):591-591 [Anon] Concern over US thalidomide approval | 1 | 0 |
| 2226 | 0 | 0 | 1425 1998 CIRCULATION 98(17):247-247 Dibbs ZI; Longo T; Muller GW; Zeldis J; Sivasubramanian N; Mann DL Thalidomide and thalidomide analogs suppress TNF alpha secretion by myocytes | 0 | 0 |
| 2227 | 0 | 0 | 1432 1998 EUROPEAN CYTOKINE NETWORK 9(3):367-367 Corral LG; Haslett PAJ; Ocampo C; Muller GW; Wong ML; Stirling D; Kaplan G Two distinct classes of thalidomide analogues which shape potent TNF-alpha inhibitory activity, modulate other cytokines differently | 0 | 0 |
| 2228 | 0 | 0 | 1434 1998 FASEB JOURNAL 12(4):A262-A262 Rowland TL; McHugh SM; Ewan PW; Lachmann PJ; Dearman RJ; Kimber I Down-regulation of T-cell and non-T-cell derived tumor necrosis factor alpha by thalidomide and dexamethasone | 0 | 0 |
| 2229 | 0 | 0 | 1435 1998 GASTROENTEROLOGY 114(4):A1008-A1008 Kenet G; Avni Y; Aeed H; Shirin H; Matas Z; Zaidel L; Galor S; Hershkovitz R; Bruck R Iodoacetamide-induced colitis in rats is inhibited by thalidomide. | 0 | 0 |
| 2230 | 0 | 0 | 1436 1998 GEBURTSHILFE UND FRAUENHEILKUNDE 58(3):M55-M58 Kosenow W Forty years ago: Thalidomide and its consequences | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2231 | 0 | 0 | 1438 1998 HEPATOLOGY 28(4):460A-460A Martinez L; Lopez-Talavera JC; Martinez M; Cadelina G; Pachon JC; Esteban R; Guardia J; Groszmann RJ Amelioration of the hyperdynamic syndrome of cirrhotic rats by thalidomide. | 0 | 0 |
| 2232 | 0 | 0 | 1443 1998 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 280(10):872-872 Nightingale SL Thalidomide approved for erythema nodosum leprosum | 9 | 11 |
| 2233 | 0 | 0 | 1447 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):516-516 Wolkenstein P; Latarget J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Milpied B; Bocquet H; Revuz J Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: Overmortality in treated group. | 0 | 0 |
| 2234 | 0 | 0 | 1448 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):693-693 Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse epidermal cell apoptosis by a TNF-alpha dependent pathway. | 0 | 0 |
| 2235 | 0 | 0 | 1456 1998 JOURNAL OF VASCULAR RESEARCH 35:54-54 Baatz H; Tonnessen B; Pleyer U; Hartmann C Antiinflammatory action of thalidomide: Modulation of leukocyte-endothelium interaction | 0 | 0 |
| 2236 | 0 | 0 | 1460 1998 LANCET 352(9124):298-298 Ault A Thalidomide makes a return to US health care | 0 | 0 |
| 2237 | 0 | 0 | 1464 1998 MEDICAL LETTER ON DRUGS AND THERAPEUTICS 40(1038):103-104 [Anon] Thalidomide | 1 | 0 |
| 2238 | 0 | 0 | 1466 1998 MOLECULAR BIOLOGY OF THE CELL 9:200A-200A Wilson K; Lancaster T; Boyd M; Taylor LD Inhibition of cell-cell contacts in T lymphoblastic cells during exposure to thalidomide. | 0 | 0 |
| 2239 | 0 | 0 | 1468 1998 NATURE BIOTECHNOLOGY 16(8):695-695 [Anon] The problem with thalidomide's new incarnation | 0 | 0 |
| 2240 | 0 | 0 | 1469 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 357(4):R119-R119 Thiel R; Klug S Adhesion receptors on rat limb bud cells after treatment with a thalidomide derivative | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2241 | 0 | 0 | 1470 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 358(1):R479-R479 Bignone IM; Papale RM; Seoane M; Bazerque PM Thalidomide - New trends for therapeutical use | 0 | 0 |
| 2242 | 0 | 0 | 1471 1998 NEUROLOGY 50(4):A208-A208 Poncelet AN; Maurer TA; Wu ZQ; Ng J; Badger J; Berger TG Peripheral neuropathy in HIV-infected patients with prurigo nodularis treated with thalidomide: Clinical and electrophysiologic features | 0 | 0 |
| 2243 | 0 | 0 | 1472 1998 NEUROLOGY 50(4):A383-A384 Frennier JM; Abrey LE; Haimovitz-Friedman A; McLoughlin M; Rosenfeld MR Does thalidomide have a role in glioma angiogenesis? | 0 | 0 |
| 2244 | 0 | 0 | 1479 1999 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 217:U88-U88 Konnecke WE; Smith AM; Khetani VD A two step synthesis of thalidomide. | 0 | 0 |
| 2245 | 0 | 0 | 1480 1999 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 218:U58-U58 Luzzio FA; Thomas EM; Figg WD Stereoselective synthesis of thalidomide analogs. | 0 | 0 |
| 2246 | 0 | 0 | 1485 1999 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 159(3):A271-A271 Lindsay L; Oliver S; Freeman S; Regis J; Krauss A; Kaplan G The role of thalidomide and steroid in modulating the expression of TNF-alpha (TNA-a) and IL-6 in the hyperoxic newborn rat lung. | 0 | 0 |
| 2247 | 0 | 0 | 1491 1999 ARTHRITIS AND RHEUMATISM 42(9):S91-S91 Connolly JE; Rigby WFC Thalidomide inhibits LPS induced activation of p38 and JNK stress activated kinase pathways. | 0 | 0 |
| 2248 | 0 | 0 | 1492 1999 ARTHRITIS AND RHEUMATISM 42(9):S187-S187 Oliver SJ; Moreira A; Kaplan G Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. | 1 | 5 |
| 2249 | 0 | 0 | 1493 1999 ARTHRITIS AND RHEUMATISM 42(9):S276-S276 Oliver SJ; Moreira A; Ozawa M; Krueger JG; Kaplan G Beneficial effects of thalidomide in sarcoidosis are associated with an enhanced Th1-type immune response | 0 | 0 |
| 2250 | 0 | 0 | 1494 1999 ARTHRITIS AND RHEUMATISM 42(9):S373-S373 El Hassani S; Dougados M; Gombert B; Amor B; Breban M Treatment of severe retractory spondylarthopathy (SPA) with thalidomide: Results of an open study. | 2 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2251 | 0 | 0 | 1495 1999 ARTHRITIS AND RHEUMATISM 42(10):2259-2260 Gompel A; Frances C; Piette JC; Blanc AS; Cordoliani F; Piette AM Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al | 7 | 8 |
| 2252 | 0 | 0 | 1496 1999 ARTHRITIS AND RHEUMATISM 42(10):2260-2260 Ordi J; Cortes F; Balada E; Mauri M; Vilardell M Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al - Reply | 0 | 0 |
| 2253 | 0 | 0 | 1499 1999 BLOOD 94(10):124A-124A Juliusson G; Celsing F; Turesson I; Adriansson M; Malm C Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant. | 0 | 2 |
| 2254 | 0 | 0 | 1500 1999 BLOOD 94(10):124A-124A Neben K; Hawighorst H; Moehler TM; Egerer G; Punzel M; Van Kaick G; Ho AD; Goldschmidt H Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. | 0 | 9 |
| 2255 | 0 | 0 | 1501 1999 BLOOD 94(10):124A-125A Moehler TM; Neben K; Egerer G; Punzel M; Schmier J; Cremer F; Goldschmidt H; Ho AD Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma. | 0 | 0 |
| 2256 | 0 | 0 | 1502 1999 BLOOD 94(10):125A-125A Shima Y; Treon SP; Yoshizaki K; Tai YT; Hideshima T; Raje N; Chauhan D; Davies F; Schlossman R; Anderson KC Clinical and biological activity of thalidomide (Thal) in multiple myeloma (MM). | 0 | 11 |
| 2257 | 0 | 0 | 1503 1999 BLOOD 94(10):125A-125A Sabir T; Raza S; Anderson L; Jagannath S Thalidomide is effective in the treatment of recurrent. Refractory multiple myeloma (MM). | 0 | 7 |
| 2258 | 0 | 0 | 1504 1999 BLOOD 94(10):158A-158A Koc S; Leisenring W; Flowers ME; Sullivan KM; Martin PJ Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients. | 0 | 1 |
| 2259 | 0 | 0 | 1505 1999 BLOOD 94(10):308B-308B Coleman M; Gelfand RM; Leonard JP Combination non-myelosuppressive therapy (thalidomide, clarithromycin, dexamethasone) for plasma cell myeloma: A preliminary report. | 0 | 2 |
| 2260 | 0 | 0 | 1506 1999 BLOOD 94(10):308B-308B Chen CI; Adesanya A; Sutton DM; Brandwein J; Stewart AK Low-dose thalidomide in patients with advanced, refractory multiple myeloma. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2261 | 0 | 0 | 1507 1999 BLOOD 94(10):311B-311B Kanard AM; Kane G; Thome SD; Goudreau J; Markovic SN Thalidomide associated with seizures and neuroradiologic features suggestive of reversible posterior leukoencephalopathy syndrome (RPLS) in the setting of multiple myeloma and renal failure. | 0 | 1 |
| 2262 | 0 | 0 | 1508 1999 BLOOD 94(10):314B-315B Srkalovic G; Karam MA; McLain DA; Hussein MA Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM). | 0 | 1 |
| 2263 | 0 | 0 | 1509 1999 BLOOD 94(10):315A-315A Cheng D; Kini AR; Rodriguez J; Burt RK; Peterson LC; Traynor AE Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. | 0 | 8 |
| 2264 | 0 | 0 | 1510 1999 BLOOD 94(10):316A-316A Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed and refractory myeloma. | 0 | 9 |
| 2265 | 0 | 0 | 1511 1999 BLOOD 94(10):316B-316B Wu K; Schaafsma MR; Smit WM; Neef C; Richel DJ Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM). | 0 | 1 |
| 2266 | 0 | 0 | 1512 1999 BLOOD 94(10):316A-316A Durie BGM; Stepan DE Efficacy of low dose thalidomide (T) in multiple myeloma. | 0 | 18 |
| 2267 | 0 | 0 | 1513 1999 BLOOD 94(10):317A-317A Schiller G; Vescio R; Berenson J Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. | 0 | 8 |
| 2268 | 0 | 0 | 1514 1999 BLOOD 94(10):317A-317A Yaccoby S; Johnson CL; Mahaffey SC; Barlogie B; Epstein J Thalidomide metabolism and its anti-myeloma efficacy in vivo. | 0 | 1 |
| 2269 | 0 | 0 | 1515 1999 BLOOD 94(10):507A-507A Thomas DA; Aguayo A; Estey E; Albitar M; O'Brien S; Giles FJ; Beran M; Cortes J; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide as anti-angiogenesis therapy (RX) in refractory or relapsed leukemias. | 0 | 5 |
| 2270 | 0 | 0 | 1516 1999 BLOOD 94(10):578A-578A Munshi N; Desikan R; Anaissie E; Zangari M; Badros A; Lim S; Toor A; Morris C; Eddlemon P; Ayers D; Roberson P; Barlogie B Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF as part of Total Therapy II in newly diagnosed multiple myeloma (MM): Influence of thalidomide (THAL) administration. | 0 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2271 | 0 | 0 | 1517 1999 BLOOD 94(10):603A-603A Desikan R; Munshi N; Zeldis J; Eddlemon P; Badros A; Zangari M; Singhal S; Mehta J; Ayers D; Lim S; Wilson C; Anaissie E; Crowley J; Barlogie B Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. | 0 | 3 |
| 2272 | 0 | 0 | 1518 1999 BLOOD 94(10):604A-604A Weber DM; Gavino M; Delasalle K; Rankin K; Giralt S; Alexanian R Thalidomide alone or with dexamethasone for multiple myeloma. | 0 | 27 |
| 2273 | 0 | 0 | 1519 1999 BLOOD 94(10):661A-661A Raza A; Lisak L; Andrews C; Little L; Muzammil M; Alvi S; Mazzoran L; Zorat F; Akber A; Ekbal M; Razvi S; Venugopal P Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS). | 0 | 9 |
| 2274 | 0 | 0 | 1520 1999 BLOOD 94(10):702A-702A Thomas DA; Aguayo A; Giles FJ; Albitar M; O'Brien S; Cortes J; Faderl S; Bivins C; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). | 0 | 15 |
| 2275 | 0 | 1 | 1531 1999 CLINICAL REHABILITATION 13(3):250-252 Newman RJ Shoulder joint replacement for osteoarthrosis in association with thalidomide-induced phocomelia | 0 | 0 |
| 2276 | 0 | 0 | 1539 1999 GASTROENTEROLOGY 116(4):A745-A745 Kane SV; Ehrenpreis ED; Cohen LB; Hanauer SB; Cohen RD Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD) | 2 | 5 |
| 2277 | 0 | 0 | 1540 1999 GASTROENTEROLOGY 116(4):A767-A767 Macumber C; Wettstein AP; Vickers CR; Hing M; Edwards PD; Byrnes DJ; Meagher AP Thalidomide-effective therapy in chronic resistant inflammatory bowel disease. Department of gastroenterology. St. Vincent's Hospital, Sydney, Australia. | 2 | 3 |
| 2278 | 0 | 0 | 1541 1999 GASTROENTEROLOGY 116(4):A837-A837 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Papadakis KA; Zeldis JB; Targan SR An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-department Crohn's disease (CD) | 3 | 0 |
| 2279 | 0 | 0 | 1542 1999 GASTROENTEROLOGY 116(4):A843-A843 Wedel S; Bauditz J; Suk A; Lochs H Efficacy of thalidomide in Crohn's disease. | 2 | 3 |
| 2280 | 0 | 0 | 1555 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S84-S84 Velez G; Robinson MR; Durbin T; Yuan P; Sung C; Whitcup SM Thalidomide-sustained release devices for choroidal neovascularization; An in-vitro analysis | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2281 | 0 | 0 | 1556 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S224-S224 Spraul CW; Kaven C; Amann J; Lang GK; Lang GE Effect of thalidomide, octreotide, and decortine on the migration and proliferation of RPE cells in vitro | 0 | 0 |
| 2282 | 0 | 0 | 1558 1999 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 103(1):S20-S20 Martinez A; Hernandez T; Hernandez V; Espinosa F Thalidomide for pertinacious vasculitic syndrome secondary to coxsackie A virus infection. | 0 | 0 |
| 2283 | 0 | 0 | 1576 1999 LANCET 354(9182):925-925 Larkin M Low-dose thalidomide seems to be effective in multiple myeloma | 9 | 14 |
| 2284 | 0 | 0 | 1577 1999 LANCET 354(9191):1705-1705 Larkin M Thalidomide continues to look promising as an anticancer agent | 1 | 1 |
| 2285 | 0 | 0 | 1580 1999 MOLECULAR BIOLOGY OF THE CELL 10:75A-75A Taylor LD; Settles B; Wilson K; Mack C Investigation of the inhibition of cell adhesion by the Anti-TNF-alpha agent thalidomide utilizing in vitro fluorescence-based assays. | 0 | 0 |
| 2286 | 0 | 0 | 1587 1999 NEUROLOGY 52(6):A424-A425 Li HW; Zhu LX; Karpati G; Nalbantoglu J Effect of thalidomide on growth of experimental intracerebral gliomas | 0 | 0 |
| 2287 | 0 | 0 | 1590 1999 ONCOLOGY-NEW YORK 13(5):744-744 [Anon] Thalidomide shows promising results in patients with multiple myeloma | 0 | 0 |
| 2288 | 0 | 0 | 1593 1999 PEDIATRIC RESEARCH 45(4):67A-67A Jakkula M; Le Cras TD; Abman SH Effects of fumagillin and thalidomide treatment on alveolarization in the developing rat lung | 0 | 4 |
| 2289 | 0 | 0 | 1605 2000 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 219:U227-U227 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites: Preparation of (+)-2-(N-phthalimido)- 4-hydroxyglutamic acid derivatives. | 0 | 0 |
| 2290 | 0 | 0 | 1606 2000 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 220:U96-U96 Luzzio FA; Thomas EM; Figg WD Thalidomide analogs and metabolites: Cyclic and acyclic derivatives of 2S, 3S-2-N-phthalimido(3-hydroxy)ornithine. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2291 | 0 | 0 | 1612 2000 AMERICAN JOURNAL OF HUMAN GENETICS 67(4):134-134 Nippert I 40 years later: The health related quality of life of women affected by Thalidomide. | 0 | 0 |
| 2292 | 0 | 0 | 1618 2000 ANNALS OF ONCOLOGY 11:54-54 Martinelli G; Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F Clinical efficacy of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis | 0 | 0 |
| 2293 | 0 | 0 | 1619 2000 ANNALS OF ONCOLOGY 11:60-60 Gasparini G; Gilberti S; Vitale S; Arena MG; Fanelli M; Ranieri G; Gattuso D; Biondi E; Morabito A Antitumoral activity of Thalidomide in patients affected by refractory breast cancer nad recurrent high grade gliomas. | 0 | 0 |
| 2294 | 0 | 0 | 1620 2000 ANNALS OF ONCOLOGY 11:96-96 Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F; Martinelli G Clinical efficacy and biologic activity of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis. | 0 | 0 |
| 2295 | 0 | 0 | 1621 2000 ANNALS OF ONCOLOGY 11:96-96 Galani E; Grigoraki V; Kiamouris C; Samantas E; Economou O; Papdimitriou C; Gika D; Anagnostopoulos N; Dimopoulos M Thalidomide and dexamethasone combination for refractory multiple myeloma. | 0 | 0 |
| 2296 | 0 | 0 | 1627 2000 ARTHRITIS AND RHEUMATISM 43(9):S117-S117 Lowe D; Kredich DW; Schanberg LE Thalidomide: An effective and safe agent for the treatment of pediatric mixed connective tissue disease. | 0 | 0 |
| 2297 | 0 | 0 | 1628 2000 ARTHRITIS AND RHEUMATISM 43(9):S396-S396 Huang F; Gu J; Braun J; Sieper J; Yu DT Identifying the targets of thalidomide and anti-TNF alpha antibody treatments in ankylosing spondylitis (AS). | 2 | 5 |
| 2298 | 0 | 0 | 1633 2000 BLOOD 96(11):146A-146A Raza A; Lisak L; Little L; Ekbal M; du Rant M; Ali E; Nascimben F; Tareen M; Venugopal P Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS). | 0 | 6 |
| 2299 | 0 | 0 | 1634 2000 BLOOD 96(11):146A-146A Mundle S; Zorat F; Shetty V; Allampallam K; Alvi S; Lisak L; Little L; Dean L; Nascimben F; Ekbal M; duRandt M; Broderick E; Venugopal P; Raza A Biologic determinents of clinical response to thalidomide in myelodysplasia. | 0 | 3 |
| 2300 | 0 | 0 | 1635 2000 BLOOD 96(11):167A-167A Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2301 | 0 | 0 | 1636 2000 BLOOD 96(11):167A-167A Coleman M; Leonard JP; Nahum K; Michaeli J Non-myelosuppressive therapy with BLT-D (Biaxin (R), low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma. | 0 | 10 |
| 2302 | 0 | 0 | 1637 2000 BLOOD 96(11):167A-167A Weber DM; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide with dexamethasone for resistant multiple myeloma. | 0 | 26 |
| 2303 | 0 | 0 | 1638 2000 BLOOD 96(11):167A-167A Yakoub-Agha I; Attal M; Dumontet C; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux I; Bay JO; Monconduit M; Harousseau JL; Duguet C; Facon T Thalidomide in patients with advanced myeloma: Survival prognostic factors. | 0 | 11 |
| 2304 | 0 | 0 | 1639 2000 BLOOD 96(11):168A-168A Kropff MH; Innig G; Mitterer M; Straka C; Ostermann H; Koch OM; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. | 0 | 7 |
| 2305 | 0 | 0 | 1640 2000 BLOOD 96(11):168A-168A Weber DM; Rankin K; Gavino M; Delasalle K; Aguayo A; Albitar M; Alexanian R Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM). | 0 | 10 |
| 2306 | 0 | 0 | 1641 2000 BLOOD 96(11):168A-168A Rajkumar SV; Hayman S; Fonseca R; Dispenzieri A; Lacy MQ; Geyer S; Wellik L; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM). | 0 | 24 |
| 2307 | 0 | 0 | 1642 2000 BLOOD 96(11):168A-169A Raza SN; Veksler Y; Sabir T; Li ZJ; Anderson L; Jagannath S Durable response to thalidomide in relapsed/refractory multiple myeloma (MM). | 0 | 7 |
| 2308 | 0 | 0 | 1643 2000 BLOOD 96(11):232B-232B Venugopal P; Sivaraman S; Gladstone B; Jajeh A; Huang XK; Brien TO; ODonnell K; Gregory S; Preisler H Thalidomide (T) influences antigen expression on tumor cells from chronic lymphocytic leukemia. | 0 | 0 |
| 2309 | 0 | 0 | 1644 2000 BLOOD 96(11):260B-260B Dourado CMC; Seixas-Silva JA; Besa EC Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. | 0 | 1 |
| 2310 | 0 | 0 | 1645 2000 BLOOD 96(11):261B-261B Lisak LA; Little L; Dean L; Ekbal M; duRandt M; Hussain M; Kaistha V; Raza A Delayed responses to thalidomide in patients with myelodysplastic syndromes. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2311 | 0 | 0 | 1646 2000 BLOOD 96(11):266B-266B Canepa L; Ballerini F; Varaldo R; Grasso R; Clavio M; Miglino M; Pierri I; Gobbi M Myelofibrosis: Report of five cases treated with thalidomide. | 0 | 1 |
| 2312 | 0 | 0 | 1647 2000 BLOOD 96(11):285B-285B Badros A; Zangari M; Bodenner D; Siegel E; Spoon D; Toor A; Desikan R; Arnold E; Anaissie E; Zeldis J; Tricot G; Barlogie B Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. | 0 | 3 |
| 2313 | 0 | 0 | 1648 2000 BLOOD 96(11):286B-286B Dimopoulos MA; Viniou N; Zomas A; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotides P Treatment of Waldenstrom's macroglobulinemia with thalidomide. | 0 | 10 |
| 2314 | 0 | 0 | 1649 2000 BLOOD 96(11):288B-288B Gibson RK; Alley L; Shuman HW Thalidomide (Thal) monotherapy is effective in previously treated recurrent multiple myeloma (MM). | 0 | 0 |
| 2315 | 0 | 0 | 1650 2000 BLOOD 96(11):289B-289B Kakimoto T; Hattori Y; Okamoto S; Kamata T; Satoh N; Takayama N; Matsushita H; Yamada T; Du WL; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma. Decreased plasma concentration of angiogenic growth factors and clinical response. | 0 | 0 |
| 2316 | 0 | 0 | 1651 2000 BLOOD 96(11):290B-290B Linder O; Tidefelt U Thalidomide combined with dexamethasone and pamidronate to patients with advanced myeloma, better than thalidomide alone? | 0 | 0 |
| 2317 | 0 | 0 | 1652 2000 BLOOD 96(11):290B-290B Moehler TM; Neben K; Hawighorst H; Egerer G; van Kaick G; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma. | 0 | 5 |
| 2318 | 0 | 0 | 1653 2000 BLOOD 96(11):290B-290B Leleu X; Cornillon J; Magro L; Guillerm G; Dalle JH; Fenaux P; Jouet JP; Bauters F; Facon T; Yakoub-Agha I Is thalidomide 50 mg/d as a minimal first dose effective in advanced myeloma? | 0 | 2 |
| 2319 | 0 | 0 | 1654 2000 BLOOD 96(11):292B-292B Palumbo A; Giaccone L; Bertola A; Bringhen S; Rus C; Triolo S; Pileri A; Boccadoro M Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma. | 0 | 6 |
| 2320 | 0 | 0 | 1655 2000 BLOOD 96(11):293B-293B Prince HM; Biagi JJ; Mitchell P; Mileshkin L; Seymour JF; Januszewicz EH; Wolf MM; Westerman DA Interferon-alpha-2b (IF) can be combined with thalidomide (Thal) in patients with multiple myeloma (MM). | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2321 | 0 | 0 | 1656 2000 BLOOD 96(11):294B-294B Rodriguez J; Oyama Y; Burt RK; Traynor AE Achievement of maximal disease response to thalidomide is limited by patient tolerance more often than disease resistance. | 0 | 4 |
| 2322 | 0 | 0 | 1657 2000 BLOOD 96(11):294B-295B Srkalovic G; Karam MA; Trebisky BM; Hussein MA Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD). | 0 | 1 |
| 2323 | 0 | 0 | 1658 2000 BLOOD 96(11):296B-296B Vescio RA; Berenson JR Thalidomide is an effective agent for patients with primary amyloidosis. | 0 | 1 |
| 2324 | 0 | 0 | 1659 2000 BLOOD 96(11):296B-296B Zangari M; Anaissie E; Desikan R; Badros A; Morris C; Munshi N; Gopal AV; Fink L; Spoon D; Tricot G; Barlogie B Thalidomide-induced hypercoagulability in multiple myeloma (MM). | 0 | 3 |
| 2325 | 0 | 0 | 1660 2000 BLOOD 96(11):296B-296B Tosi P; Ronconi S; Zamagni E; Cellini C; Tura S; Cavo M Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma. | 0 | 3 |
| 2326 | 0 | 0 | 1661 2000 BLOOD 96(11):304A-304A Hideshima T; Chauhan D; Shima Y; Noopur R; Davies FE; Tai YT; Treon SP; Lin BK; Schlossman RL; Richardson PG; Gupta D; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and its analogs overcome drug resistance of human multiple myeloma (MM) cells to conventional therapy. | 0 | 0 |
| 2327 | 0 | 0 | 1662 2000 BLOOD 96(11):323A-323A Estey E; Albitar M; Cortes J; Giles F; Thomas D; Koller C; Beran M; Kantarjian H Addition of thalidomide(T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS. | 0 | 13 |
| 2328 | 0 | 0 | 1663 2000 BLOOD 96(11):356A-356A Alvi S; Henderson B; Shaher A; Dangerfield B; Broderick E; Jafri N; Tareen M; Du Randt M; Galili N; Borok RZ; Raza A Determination of clonality in stromal and parenchymal cells pre and post thalidomide treatment in myelodysplasia. | 0 | 0 |
| 2329 | 0 | 0 | 1664 2000 BLOOD 96(11):359A-359A Alvi S; Shaher A; Henderson B; Dar S; Zorat F; Broderick E; Lisak L; Du Randt M; Reddy P; Mundle S; Galili N; Borok RZ; Raza A Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. | 0 | 1 |
| 2330 | 0 | 0 | 1665 2000 BLOOD 96(11):364A-364A Rajkumar SV; Timm M; Mesa RA; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Gertz MA; Kyle RA; Griepp PR; Witzig TE Effect of thalidomide on myeloma cell apoptosis and VEGF secretion. | 0 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2331 | 0 | 0 | 1666 2000 BLOOD 96(11):364A-364A Yata K; Otsuki T; Yamada O; Yawata Y Expression of angiogenic factors including VEGFs, effects of anti-VEGF-A MoAb, hypoxia, and thalidomide on myeloma cells. | 0 | 0 |
| 2332 | 0 | 0 | 1667 2000 BLOOD 96(11):366A-366A Petrucci MT; Ricciardi MR; Gregorj C; Palumbo G; Del Bianco P; Cartoni C; Mandelli F; Tafuri A Thalidomide effects on apoptosis in multiple myeloma: Ex-vivo and in vitro study. | 0 | 1 |
| 2333 | 0 | 0 | 1668 2000 BLOOD 96(11):367B-367B Castro J; Talavera A; Tejeda C; Cortes L; Fradera J; Velez-Garcia E Preliminary experience of the use of thalidomide maintenance therapy after autologous transplant in patients with multiple myeloma (MM). | 0 | 0 |
| 2334 | 0 | 0 | 1669 2000 BLOOD 96(11):368B-368B Dmoszynska A; Hus M; Legiec W; Walter-Croneck A; Wach M Delayed stem cell transplantation in patients with relapsed or refractory multiple myeloma using thalidomide as a preparative regimen. | 0 | 0 |
| 2335 | 0 | 0 | 1670 2000 BLOOD 96(11):514A-514A Barlogie B; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 14 |
| 2336 | 0 | 0 | 1671 2000 BLOOD 96(11):579A-+ Lentzsch S; Podar K; Davies FE; Hideshima T; Tai YT; Chauhan D; Lin BK; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Muller GW; Stirling DI; Anderson KC Immunomodulatory derivatives (IMiDs) of thalidomide (Thal) inhibit the proliferation of multiple myeloma (MM) cell lines and block VEGF-induced activation of the MAPK-pathway. | 0 | 2 |
| 2337 | 0 | 0 | 1672 2000 BLOOD 96(11):579A-+ Payvandi F; Wu L; Gupta D; Hideshima T; Haley M; Muller G; Chen R; Anderson KC; Stirling S Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. | 0 | 1 |
| 2338 | 0 | 0 | 1673 2000 BLOOD 96(11):579A-+ Shaughnessy J; Zhan F; Tian E; Bumm K; Muller G; Stirling D; Tricot G; Barlogie B Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD. | 0 | 2 |
| 2339 | 0 | 0 | 1674 2000 BLOOD 96(11):746A-746A Piccaluga PP; Finelli C; Ricci P; Cavo M; Pileri SA; Isidori A; Malagola M; Grafone T; Tura S; Visani G Antiangiogenic therapy with thalidomide improves anemia, thrombocytopenia, hyperleucocytosis, splenomegaly in idiopathic myelofibrosis. | 0 | 4 |
| 2340 | 0 | 0 | 1675 2000 BLOOD 96(11):746A-746A Barosi G; Grossi A; Comotti B; Marchetti M Thalidomide in patients with myelofibrosis with myeloid metaplasia. | 0 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2341 | 0 | 0 | 1676 2000 BLOOD 96(11):837A-837A Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin BK; Podar K; Chauhan D; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Richardson PG; Schlossman RL; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and immunomodulatory derivatives (IMiDS) augment natural killer (NK) cell cytotoxicty in multiple myeloma (MM). | 0 | 2 |
| 2342 | 0 | 0 | 1682 2000 BRITISH JOURNAL OF CANCER 83:31-31 Stebbing J; Benson C; Eisen T; Mak I; Pyle L; Smalley K; Gore ME A phase II study of high dose oral thalidomide in patients with metastatic renal cell carcinoma (RCC) or metastatic melanoma (MM) | 0 | 0 |
| 2343 | 0 | 0 | 1687 2000 CA-A CANCER JOURNAL FOR CLINICIANS 50(1):3-3 [Anon] Once again, thalidomide in the news | 0 | 0 |
| 2344 | 0 | 0 | 1691 2000 CHEMISTRY & INDUSTRY (16):522-522 [Anon] Health - Thalidomide patents granted in US | 0 | 0 |
| 2345 | 0 | 0 | 1695 2000 CLINICAL CANCER RESEARCH 6:4522S-4523S Figg WD; Dahut W; Libutti SK; Carrasquillo J; Bacharach S; Kurdziel K; Huebsch F; Kruger EA; Pluda J; Reed E Thalidomide, an angiogenesis inhibitor, has activity in metastatic prostate cancer. | 0 | 0 |
| 2346 | 0 | 0 | 1698 2000 CLINICAL INFECTIOUS DISEASES 31(1):312-312 Joyce MP; Sandoval FG; Shannon EJ Thalidomide's effect on immune parameters in untreated lepromatous leprosy and erythema nodosum leprosum | 0 | 0 |
| 2347 | 0 | 0 | 1699 2000 CLINICAL PHARMACOLOGY & THERAPEUTICS 67(2):157-157 Noormohamed FH; Yoder L; Kook KA; Thomas SD Thalidomide pharmacokinetics in leprosy patients. | 0 | 0 |
| 2348 | 0 | 0 | 1702 2000 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 125:S26-S27 Eichhorn A; Kirch W Thalidomide for Behcets syndrome | 0 | 0 |
| 2349 | 0 | 0 | 1703 2000 DEVELOPMENTAL DYNAMICS 219(3):443-443 Fillmore BJ; Stephens TD Angiogenic integrin avb3 as a site of the teratogenic action of thalidomide | 0 | 0 |
| 2350 | 0 | 0 | 1704 2000 DIABETES 49:A434-A434 Iqbal N; Boden G Thalidomide impairs insulin stimulated glucose uptake in patients with type 2 diabetes (T2DM) by inhibiting glycogen synthesis | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2351 | 0 | 0 | 1706 2000 DRUG NEWS & PERSPECTIVES 13(3):146-146 [Anon] Celgene's IMiDS and thalidomide show activity as COX-2 inhibitors | 1 | 0 |
| 2352 | 0 | 0 | 1710 2000 EUROPEAN HEART JOURNAL 21:367-367 Vescovo G; Ceconi C; Ferrari R; Ambrosio GB; Ravara B; Angelini A; Corti A; Rossini K; Sandri M; Leprotti C; Dalla Libera L Does thalidomide block apoptosis and prevent from the development of skeletal muscle myopathy in chronic heart failure? | 0 | 0 |
| 2353 | 0 | 0 | 1712 2000 EXPERIMENTAL HEMATOLOGY 28(7):103-104 Raza A; Lisak L; Little L; Andrews C; Meyer P; Ekbal M; Venugopal P Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide | 0 | 0 |
| 2354 | 0 | 0 | 1713 2000 EXPERIMENTAL HEMATOLOGY 28(7):110-110 Janssen WE; Dalton WS Improved blood hematopoietic progenitor mobilization in myeloma patients following treatment with thalidomide | 0 | 0 |
| 2355 | 0 | 0 | 1714 2000 FASEB JOURNAL 14(8):A1512-A1512 Cornely KA; Bennett NS Thalidomide makes a comeback: A case study exercise that integrates biochemistry and organic chemistry | 0 | 0 |
| 2356 | 0 | 0 | 1715 2000 GASTROENTEROLOGY 118(4):A580-A580 Bauditz L; Wedel S; Suk A; Lochs H Cytokine profiles under treatment with Thalidomide steroid-resistant Crohn's disease. | 0 | 0 |
| 2357 | 0 | 0 | 1716 2000 GASTROENTEROLOGY 118(4):A582-A582 Kam LY; Vasiliauskas EA; Abreu MT; Hassard PV; Zeldis J; Targan SR Open labeled pilot study of thalidomide(thal) as a novel therapy for medically resistant ulcerative colitis (UC). | 1 | 6 |
| 2358 | 0 | 0 | 1717 2000 GASTROENTEROLOGY 118(4):A586-A586 Prehn JL; Muller GW; Man HW; Stirling DJ; Targan SR Thalidomide analogs, but not thalidomide itself, are potent inhibitors of lamina propria mononuclear cell (LPMC) TNF-A and IFN-Gamma production in response to T cell stimuli. | 0 | 0 |
| 2359 | 0 | 0 | 1719 2000 GESUNDHEITSWESEN 62(8-9):A87-A87 Edler B; Teige B; Nippert I Study on health-related quality of life among women with developmental retardation - Case of thalidomide victims | 0 | 0 |
| 2360 | 0 | 0 | 1722 2000 HEPATOLOGY 32(4):410A-410A Enomoto N; Ikejima K; Hirose M; Ishikawa M; Konno A; Matsuyama S; Shimizu H; Kitamura T; Takei Y; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of TNF-A production by Kupffer cells. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2361 | 0 | 0 | 1729 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S180-S180 Velez G; King BA; Yuan P; Whitcup SM; Robison MR Thalidomide analogue (EM-138) sustained release implants to treat choroidal neovascularization associated with macular degeneration | 0 | 0 |
| 2362 | 0 | 0 | 1730 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Spraul CW; Kaven C; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human RPE cell proliferation. | 0 | 0 |
| 2363 | 0 | 0 | 1731 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Jakobezyk-Zmija M; Kaven C; Spraul CW; Lang GK; Lang GE Effect of thalidomide and prednisolone on the secretion of growth factors by human RPE cells in vitro | 0 | 0 |
| 2364 | 0 | 0 | 1732 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S684-S684 Tham VMB; Tong JT; Giese MJ; Tran MK; Fardin B; Taban R; Rayner SA; Mondino BJ The effect of thalidomide on corneal graft rejection in rabbit eyes | 0 | 0 |
| 2365 | 0 | 0 | 1752 2000 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 35(2):172A-173A Bozkurt B; Chee A; Lee-Jackson D; Deswal A; Zeldis JB; Mann DL Results of an open label dose response study of thalidomide in patients with advanced heart failure and elevated levels of TNF | 0 | 2 |
| 2366 | 0 | 0 | 1755 2000 LEPROSY REVIEW 71:S120-S120 Ottenhoff THM; Kaplan G; Gillis TP Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions - Discussion | 0 | 0 |
| 2367 | 0 | 0 | 1761 2000 MOLECULAR BIOLOGY OF THE CELL 11:112A-112A Stevenson AN; Odoms S; Ezell T; Valentine S; Taylor L Does thalidomide reduce inflammation by altering cell adhesion molecule expression and cell-cell contacts on CEM cells? | 0 | 0 |
| 2368 | 0 | 0 | 1762 2000 MOLECULAR BIOLOGY OF THE CELL 11:452A-452A Ezell TN; Odoms S; Davis M; Taylor L Human T leukemic cells exhibit biochemical changes consistent with apoptosis after treatment with tumor necrosis factor alpha and thalidomide. | 0 | 0 |
| 2369 | 0 | 0 | 1765 2000 NEUROLOGY 54(7):A12-A13 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips P A phase I study of thalidomide for the treatment of plexiform neurofibroma in patients with neurofibromatosis 1 (NF1) | 0 | 0 |
| 2370 | 0 | 0 | 1770 2000 ONCOLOGY-NEW YORK 14(3):452-452 [Anon] Substantial activity of thalidomide in multiple myeloma, study shows | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2371 | 0 | 0 | 1771 2000 ONCOLOGY-NEW YORK 14(4):479-479 [Anon] Thalidomide active in advanced multiple myeloma | 0 | 0 |
| 2372 | 0 | 0 | 1772 2000 ONCOLOGY-NEW YORK 14(7):1081-1081 [Anon] Expanded data on thalidomide in advanced myeloma | 0 | 0 |
| 2373 | 0 | 0 | 1773 2000 ONCOLOGY-NEW YORK 14(12):9-10 Rajkumar SV Thalidomide in hematologic and oncologic disease - Proceedings of an Investigators' Meeting - May 20, 2000, New Orleans - Introduction | 2 | 2 |
| 2374 | 0 | 0 | 1782 2000 PEDIATRIC RESEARCH 47(4):264A-264A Hanekom W; Ganiso B; Appolis P; Hughes J; Allin R; Goddard E; Haslett P; Hussey G; Kaplan G Safety and immune effects of thalidomide in HIV-infected children | 0 | 0 |
| 2375 | 0 | 10 | 1787 2000 SEMINARS IN HEMATOLOGY 37(1):22-25 Alexanian R; Weber D Thalidomide for resistant and relapsing myeloma | 22 | 26 |
| 2376 | 0 | 68 | 1790 2000 SOCIAL STUDIES OF SCIENCE 30(1):41-71 Timmermans S; Leiter V The redemption of thalidomide: Standardizing the risk of birth defects | 0 | 1 |
| 2377 | 0 | 0 | 1798 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U653-U653 Shi JD; Xiao ZL; Marks M; Kamat C; Pokala V Development of thalidomide analogs as anti-angiogenic agents. | 0 | 0 |
| 2378 | 0 | 0 | 1799 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U659-U659 Xiao ZL; Schaefer K; Li PK Solid phase synthesis of thalidomide and its analogs. | 0 | 0 |
| 2379 | 0 | 0 | 1800 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U685-U685 Luzzio FA; Figg WD; Mayorov AV; Kruger EA Thalidomide metabolites and analogs, part 3: Synthesis and antiangiogenic activity of the teratogenic and TNF-alpha-modulatory thalidomide analog EM-12. | 0 | 0 |
| 2380 | 0 | 0 | 1815 2001 ARTHRITIS AND RHEUMATISM 44(9):S125-S125 Barthel HR Successful treatment of Weber Christian disease (WCD) with thalidomide in a patient failing multiple other medical therapies | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2381 | 0 | 0 | 1816 2001 ARTHRITIS AND RHEUMATISM 44(9):S272-S272 Lehman TJ; Striegel KH; Onel KB Thalidomide therapy for corticosteroid dependent systemic onset juvenile rheumatoid arthritis | 0 | 1 |
| 2382 | 0 | 0 | 1817 2001 ARTHRITIS AND RHEUMATISM 44(9):S275-S275 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY Therapeutic effect and molecular targets of thalidomide in refractory ankylosing spondylitis (AS). | 0 | 2 |
| 2383 | 0 | 0 | 1818 2001 ARTHRITIS AND RHEUMATISM 44(9):S280-S280 Cuadrado MJ; Smith E; Gordon P; Karim Y; Khamashta MA; Hughes GRV Thalidomide: Efficacy and safety in 30 patients with lupus and skin involvement. | 0 | 0 |
| 2384 | 0 | 0 | 1833 2001 BLOOD 98(11):52B-52B Anders O; Plath F; Emmrich J; Freund M Complete remission of therapy-resistant angiodysplasia of the stomach in myelodysplastic syndrome following thalidomide. | 0 | 0 |
| 2385 | 0 | 0 | 1834 2001 BLOOD 98(11):52B-52B Arkel YS; Ku DHW; Le P Effect of thalidomide on tissue factor activity in monocytic and endothelial cell lines, and relationship to tumor necrosis factor-alpha (TNF). | 0 | 0 |
| 2386 | 0 | 0 | 1835 2001 BLOOD 98(11):161A-162A Zangari M; Siegel E; Anaissie E; Saghafifar F; Morris C; Fink L; Barlogie B; Tricot G Risk factors for deep vein thrombosis (DVT) in a large group of myeloma patients (pts) treated with thalidomide (Thal): The Arkansas experience. | 0 | 4 |
| 2387 | 0 | 0 | 1836 2001 BLOOD 98(11):162A-162A Palumbo A; Giaccone L; Bringhen S; Cavallo F; Falco P; Rus C; Bertola A; Pileri A; Boccadoro M Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma patients. | 0 | 4 |
| 2388 | 0 | 0 | 1837 2001 BLOOD 98(11):162A-162A Wechalekar AD; Sutton D; Voralia M; Stewart AK; Chen CI Intermediate dose thalidomide (200mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. | 0 | 5 |
| 2389 | 0 | 0 | 1838 2001 BLOOD 98(11):162A-162A Kakimoto T; Hattori Y; Okamoto S; Sato N; Yamaguchi M; Morita K; Yamada T; Takayama N; Shimada N; Tanigawara Y; Ikeda Y Clinical significance of serial monitoring of plasma concentration of thalidomide and angiogenic growth factors in patients with refractory myeloma. | 0 | 1 |
| 2390 | 0 | 0 | 1839 2001 BLOOD 98(11):162A-163A Rajkumar SV; Dispenzieri A; Lacy M; Geyer S; Iturria N; Fonseca R; Hayman SR; Lust JA; Kyle R; Greipp PR; Gertz MA; Witzig TE Response rate and durablity of response with thalidomide therapy for relapsed multiple myeloma (MM). | 0 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2391 | 0 | 0 | 1840 2001 BLOOD 98(11):163A-163A Tosi P; Zamagni E; Cellini C; Cangini D; Tura S; Baccarani M; Cavo M Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractor multiple myeloma. | 0 | 3 |
| 2392 | 0 | 0 | 1841 2001 BLOOD 98(11):163A-163A Alexanian R; Weber DM; Giralt S; Delasalle KB Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. | 0 | 2 |
| 2393 | 0 | 0 | 1842 2001 BLOOD 98(11):163A-163A Grosbois B; Bellissant E; Moreau P; Attal M; Zerbib R Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients. | 0 | 5 |
| 2394 | 0 | 0 | 1843 2001 BLOOD 98(11):163A-163A Durie BGM; Stepan DE Low dose thalidomide alone and in combination: Long term follow-up. | 0 | 6 |
| 2395 | 0 | 0 | 1844 2001 BLOOD 98(11):163A-163A Neben K; Moehler TM; Benner A; Kraemer A; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide (Thal) on overall survival (OS) in relapsed and refractory multiple myeloma (MM). | 0 | 0 |
| 2396 | 0 | 0 | 1845 2001 BLOOD 98(11):164A-164A Dimopoulos M; Panayiotidis P; Grigoraki V; Poziopoulos C; Xilouri I; Kiamouris C; Tassidou A; Gika D; Stefanoudaki K; Anagnostopoulos N; Anagnostou D Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma. | 0 | 7 |
| 2397 | 0 | 0 | 1846 2001 BLOOD 98(11):164A-164A Seldin DC; Choufani E; Skinner M; Wright DG; Dember L; Weisman J; Fennessey S; Finn K; Sanchorawala V A phase I/II trial of thalidomide for patients with AL amyloidosis. | 0 | 1 |
| 2398 | 0 | 0 | 1847 2001 BLOOD 98(11):182B-182B Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Yalcin A Terminal differentiation and apoptosis of myeloid leukemia induced by thalidomide and rhGM-CSF combination. | 0 | 0 |
| 2399 | 0 | 0 | 1848 2001 BLOOD 98(11):215B-215B Manson SD; Venugopal P; Gregory SA; Raza A; Sivaraman S; Preisler H Treatment of relapsed/refractory acute myeloid leukemia (AML) with thalidomide as a single agent: Clinical and biologic responses. | 0 | 0 |
| 2400 | 0 | 0 | 1849 2001 BLOOD 98(11):222B-222B Sivaraman S; Venugopal P; Hu WY; Gladstone B; Galili N; Nair A; Manjali J; Mogongwa A; Zhao HP; Manson S; Preisler H Effect of thalidomide as a single agent on serum cytokine levels in patients with relapsed acute myeloid leukemia. | 0 | 0 |
Page 8: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22